Bharat Biotech Concludes Final Analysis for COVAXIN Efficacy from Phase 3 Clinical Trialsbr br - Efficacy analysis demonstrates COVAXIN to be 77.8 effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo groupbr - Efficacy analysis demonstrates COVAXIN to be 93.4 effective against severe symptomatic COVID-19br - Safety analysis demonstrates adverse events reported were similar to placebo, with 12 of subjects experiencing commonly known side effects and less than 0.5 of subjects feeling serious adverse eventsbr - Efficacy data demonstrates 63.6 protection against asymptomatic COVID-19br - Efficacy data demonstrates 65.2 protection against the SARS-CoV-2, B.1.617.